Oil prices rebound sharply on smaller-than-feared OPEC+ output hike
Director Peter Feinberg of Immuneering Corp (NASDAQ:IMRX) reported purchasing 7,500 shares of Class A Common Stock on September 30, 2025. The shares were bought at a weighted average price of $7.0307, in a range of $7.0049 to $7.055, for a total transaction value of $52,730. The purchase comes as the stock trades near $7, following a 24% decline over the past week, though InvestingPro data shows impressive gains of over 200% year-to-date. Analysts maintain a strong buy consensus with price targets ranging from $10 to $30.
Following the transaction, Feinberg directly owns 149,266 shares of Immuneering Corp Class A Common Stock. Feinberg also indirectly owns 392,242 shares as General Partner of PF Associates L.P., 476,615 shares as General Partner of PEF LLC, and 115,441 shares as General Partner of S4K Investments LLC. The company, currently valued at $443 million, maintains healthy liquidity with a current ratio of 3.7 and operates with moderate debt levels. Discover more key metrics and 12 additional exclusive insights with InvestingPro.
In other recent news, Immuneering Corporation has announced impressive survival data from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer patients. The trial reported an 86% overall survival rate at 9 months, significantly surpassing the standard care benchmark of about 47%. Additionally, the progression-free survival rate at 9 months reached 53%, compared to the standard benchmark of approximately 29%. Following these results, Oppenheimer raised its price target for Immuneering to $30, maintaining an Outperform rating, while Mizuho reiterated its Outperform rating with a $10 price target. Immuneering also announced a proposed underwritten public offering of its Class A common stock and pre-funded warrants. In a related development, Sanofi has committed to a $25 million private investment in Immuneering’s stock at the same price as the public offering. These developments reflect a positive outlook for Immuneering’s ongoing clinical efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.